NASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis $38.71 +0.10 (+0.26%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$38.52 -0.19 (-0.48%) As of 08:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Roivant Sciences Stock (NASDAQ:ROIV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roivant Sciences alerts:Sign Up Key Stats Today's Range$37.38▼$38.7450-Day Range$33.35▼$41.8552-Week Range$19.96▼$42.50Volume8.47 million shsAverage Volume8.73 million shsMarket Capitalization$28.05 billionP/E RatioN/ADividend YieldN/APrice Target$46.82Consensus RatingModerate Buy Company Overview Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies. Roivant operates internationally, with activities spanning the United States and other markets. Matthew Gline is the company’s chief executive officer.AI Generated. May Contain Errors. Read More Roivant Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreROIV MarketRank™: 2.439658621145 of 5 starsRoivant Sciences scored higher than 49% of companies evaluated by MarketBeat, and ranked 539th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 1 strong buy rating, 10 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialRoivant Sciences has a consensus price target of $46.82, representing about 20.9% upside from its current price of $38.71.Amount of Analyst CoverageRoivant Sciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Roivant Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Roivant Sciences are expected to decrease in the coming year, from ($2.00) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is -61.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is -61.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 6.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.91% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 6.07.Change versus previous monthShort interest in Roivant Sciences has recently increased by 12.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.58 News SentimentRoivant Sciences has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Roivant Sciences this week, compared to 6 articles on an average week.Search Interest4 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,398,784.00 in company stock.Percentage Held by Insiders8.80% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ROIV Stock News HeadlinesRoivant Sciences (NASDAQ:ROIV) Stock Price Expected to Rise, Guggenheim Analyst SaysNovember 18 at 2:00 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Roivant Sciences (ROIV) and Cogent Biosciences (COGT)November 15 at 3:09 AM | theglobeandmail.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 18 at 1:00 AM | American Alternative (Ad)Roivant Sciences Insider Sold Shares Worth $12,473,272, According to a Recent SEC FilingNovember 13, 2026 | marketscreener.comMInsider Selling: Roivant Sciences (NASDAQ:ROIV) CFO Sells 125,000 Shares of StockNovember 13, 2026 | insidertrades.comHow Trial Wins And Drug Launch Revenue Will Impact Roivant Sciences Stock (ROIV)November 12, 2026 | finance.yahoo.comInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares of Company StockNovember 6, 2026 | insidertrades.comRoivant Sciences (NASDAQ:ROIV) CEO Sells $7,022,000.00 in StockOctober 23, 2026 | insidertrades.comSee More Headlines ROIV Stock Analysis - Frequently Asked Questions How have ROIV shares performed this year? Roivant Sciences' stock was trading at $21.70 on January 1st, 2026. Since then, ROIV shares have increased by 78.4% and is now trading at $38.71. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) issued its quarterly earnings results on Friday, August, 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $1.44 million for the quarter, compared to analysts' expectations of $2.06 million. Roivant Sciences had a negative net margin of 838.21% and a negative trailing twelve-month return on equity of 22.03%. Read the conference call transcript. Who are Roivant Sciences' major shareholders? Roivant Sciences' top institutional investors include State Street Corp (3.10%), Assenagon Asset Management S.A. (1.02%), Pictet Asset Management Holding SA (0.58%) and Baker BROS. Advisors LP (0.51%). Insiders that own company stock include Sciences Ltd Roivant, Vivek Ramaswamy, Financial Lp Qvt, Mayukh Sukhatme, Matthew Gline, Frank Torti, Daniel Allen Gold, Keith S Manchester, Eric Venker, Richard Pulik, Rakhi Kumar, Jennifer Humes and Melissa B Epperly. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Roivant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roivant Sciences investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Broadcom (AVGO), Energy Transfer (ET) and UiPath (PATH). Company Calendar Last Earnings8/07/2026Today11/18/2026CMD 202612/09/2026Next Earnings (Estimated)2/05/2027Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 4 weeks, ROIV's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ROIV CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees721Year Founded2014Price Target and Rating Average Price Target for Roivant Sciences$46.82 High Price Target$56.00 Low Price Target$33.00 Potential Upside/Downside+20.9%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$299.77 million Net Margins-838.21% Pretax Margin-723.39% Return on Equity-22.03% Return on Assets-20.55% Debt Debt-to-Equity RatioN/A Current Ratio15.56 Quick Ratio15.56 Sales & Book Value Annual Sales$8.26 million Price / Sales3,395.61 Cash FlowN/A Price / Cash FlowN/A Book Value$6.34 per share Price / Book6.11Miscellaneous Outstanding Shares724,560,000Free Float660,800,000Market Cap$28.05 billion OptionableOptionable Beta1.23 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ROIV) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.